SCHEMBL1247069

SCHEMBL1247069

O=C(O)Cc1ccc(CCO)s1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.49
KMT2A Q03164 4/20 0.49
MAPT P10636 4/20 0.45
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 2/20 0.45
HSD17B10 Q99714 2/20 0.45
USP2 O75604 1/20 0.45
L3MBTL1 Q9Y468 5/20 0.43
TDP1 Q9NUW8 4/20 0.43
POLB P06746 4/20 0.43
RECQL P46063 3/20 0.43
BLM P54132 1/20 0.43
APEX1 P27695 1/20 0.42
APOBEC3A P31941 1/20 0.42
APOBEC3G Q9HC16 1/20 0.42
ERAP1 Q9NZ08 1/20 0.42
RPS6KB2 Q9UBS0 1/20 0.41
ACACA Q13085 2/20 0.41
LMNA P02545 2/20 0.38
PRNP P04156 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL68973 0.87 HPGD (0.59) HPGDKMT2AMAPTALDH1A1MEN1
SCHEMBL16564107 0.83 HPGD (0.49) HPGDKMT2AMAPTALDH1A1MEN1
SCHEMBL13065318 0.83 HPGD (0.52) HPGDKMT2AMAPTALDH1A1MEN1
SCHEMBL16564192 0.82 HPGD (0.47) HPGDKMT2AMAPTALDH1A1MEN1
SCHEMBL12038476 0.77 RXFP1 (0.64) HPGDKMT2AMAPTALDH1A1TDP1
SCHEMBL16564292 0.77 HPGD (0.50) HPGDKMT2AMAPTALDH1A1MEN1
SCHEMBL11626640 0.77 HPGD (0.50) HPGDKMT2AMAPTALDH1A1MEN1
SCHEMBL6081236 0.77 HPGD (0.50) HPGDKMT2AMAPTALDH1A1MEN1
SCHEMBL9880895 0.77 HPGD (0.50) HPGDKMT2AMAPTALDH1A1MEN1
SCHEMBL8437531 0.77 HPGD (0.50) HPGDKMT2AMAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3077385-B1 HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES CHIESI FARM SPA (IT) 2017-10-04 EP disclosed
EP-3077385-B1 HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES CHIESI FARM SPA (IT) 2017-10-04 EP disclosed
EP-3077385-A1 HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES Chiesi Farmaceutici S.p.A. (IT) 2016-10-12 EP disclosed
CN-105793250-A Heteroaryl derivatives for the treatment of respiratory diseases 奇斯药制品公司 2016-07-20 CN disclosed
US-9133185-B2 Heteroaryl derivatives CHIESI FARMACEUTICI S.P.A (IT) 2015-09-15 US disclosed
US-9133185-B2 Heteroaryl derivatives CHIESI FARMACEUTICI S.P.A (IT) 2015-09-15 US disclosed
US-9133185-B2 Heteroaryl derivatives CHIESI FARMACEUTICI S.P.A (IT) 2015-09-15 US disclosed
US-20150158858-A1 HETEROARYL DERIVATIVES CHIESI FARMACEUTICI S.P.A. (IT) 2015-06-11 US disclosed
WO-2015082616-A1 HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES CHIESI FARMACEUTICI S.P.A. (IT) 2015-06-11 WO disclosed
WO-2015082616-A1 HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES CHIESI FARMACEUTICI S.P.A. (IT) 2015-06-11 WO disclosed
CN-102083839-A Compound (I) ASTRAZENECA AB 2011-06-01 CN disclosed
US-20110053909-A1 Compounds - 801 PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) 2011-03-03 US disclosed
WO-2011012896-A2 COMPOUNDS - 801 ASTRAZENECA AB (SE) 2011-02-03 WO disclosed
EP-2242759-A1 COMPOUNDS AstraZeneca AB (SE) 2010-10-27 EP disclosed
US-20090298807-A1 Compounds ASTRAZENECA AB (SE) 2009-12-03 US disclosed
US-20090298807-A1 Compounds ASTRAZENECA AB (SE) 2009-12-03 US disclosed
US-20090298807-A1 Compounds ASTRAZENECA AB (SE) 2009-12-03 US disclosed
WO-2009098448-A1 COMPOUNDS ASTRAZENECA AB (SE) 2009-08-13 WO disclosed
WO-2009098448-A1 COMPOUNDS ASTRAZENECA AB (SE) 2009-08-13 WO disclosed
WO-2008096129-A1 NITROGEN CONTAINING HETROCYCLIC COMPOUNDS USEFUL AS BIFUNCTIONAL MODULATORS OF M3 RECEPTORS AND BETA- 2 RECEPTORS ARGENTA DISCOVERY LTD (GB) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298807-A1 Compounds PKD1, SLC10A1, ABCB11 HPGD 144/4885KMT2A 4286/4885MAPT 3010/4885
US-20110053909-A1 Compounds - 801 ADRA2C, ADRB2, ADRB1 HPGD 702/4885KMT2A 2392/4885MAPT 1487/4885
US-20150158858-A1 HETEROARYL DERIVATIVES PDE4A, PDE4B, PDE3A HPGD 356/4885KMT2A 2493/4885MAPT 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.